KRAS and cancer: In other cancers, a proportion of KRAS-mutant cell lines resistant to trametinib was found to have a mesenchymal gene expression signature (63), and dasatinib has been reported to overcome mesenchymal transition–associated resistance to erlotinib in non–small cell lung cancers (64).